The Cancer Breakthroughs 2020 Program is one of the most comprehensive cancer collaborative initiatives launched to date, seeking to accelerate the potential of combination immunotherapy as the next generation standard of care in cancer patients.
Ultimately, the aim of the “Cancer Breakthroughs 2020” is to win the war on cancer — to get to a point in the very near future when we are managing cancer the same way we might manage any chronic disease, such as diabetes or asthma. When we can finally stop the toxic therapies, such as chemotherapy and radiation that decimate the immune system, and instead, rally the full power of the immune system and the body’s natural killer cells to fight off the cancer the way they were designed to do, the patient is not only surviving the diagnosis, but living – even thriving – with cancer.
Our Role in the Cure
Altor BioScience is part of an unprecedented collaboration across pharma, community and academic oncology, government, and scientific communities. This joint approach provides researchers with necessary testing materials and patients with more opportunities to participate through local facilities and wider insurance coverage. Oncologists receive real time trial results, and patients have hope for more positive outcomes.